Proteoglycan 4 (PRG4) treatment enhances wound closure and tissue regeneration.

"Competing interests S.A., T.A.S., J.A.B., and R.J.K., have authored patents related to rhPRG4, and T.A.S. hold equity in Lubris BioPharma LLC. T.A.S. is also a paid consultant for Lubris BioPharma, Authors declare that they have no competing interests in additional to those listed above."

"We would like to thank Lubris LLC for providing the recombinant human lubricin; Mark Fritzler of Eve Technologies for assistance with the Luminex analysis; Dr. Yiping Liu of the Cumming School of Medicine Flow Cytometry Facility for assistance with FACS and the Cumming School of Medicine ARC staff for assistance with animal husbandry. Funding was provided by the Natural Sciences and Engineering Research Council (NSERC) of Canada RGPIN-2014-04586 (RJK); Canada Foundation for Innovation (RJK); Calgary Foundation, Grace Glaum Professorship (R.J.K.); Canadian Institutes for Health Research 01309MOP-311542-DIB-CBBA-170939 (RJK); Cumming School of Medicine PDF award (SA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author contributions: Conceptualization: S.A., R.J.K.; Methodology: S.A., R.J.K., C.L., P.T., S.C.R., K.I., P.S.; Investigation: R.J.K., S.A., C.L., A.O.M., S.S., P.T., S.C.R., N.N., J.M.C., K.I., P.S.; Visualization: R.K., S.A., E.L., T.M.U., P.S., T.A.S., J.A.B.; Funding acquisition: R.K., S.A.; Project administration: R.K.; Supervision: R.K., T.M.U., T.A.S., J.A.B.; Writing—original draft: RK, SA., CL., TAS., JAB.; Writing—review & editing: S.A., C.L., P.S., T.A.S., J.A.B."